240 related articles for article (PubMed ID: 25506699)
1. Apoptotic efficacy of etomoxir in human acute myeloid leukemia cells. Cooperation with arsenic trioxide and glycolytic inhibitors, and regulation by oxidative stress and protein kinase activities.
Estañ MC; Calviño E; Calvo S; Guillén-Guío B; Boyano-Adánez Mdel C; de Blas E; Rial E; Aller P
PLoS One; 2014; 9(12):e115250. PubMed ID: 25506699
[TBL] [Abstract][Full Text] [Related]
2. 2-Deoxy-D-glucose cooperates with arsenic trioxide to induce apoptosis in leukemia cells: involvement of IGF-1R-regulated Akt/mTOR, MEK/ERK and LKB-1/AMPK signaling pathways.
Estañ MC; Calviño E; de Blas E; Boyano-Adánez Mdel C; Mena ML; Gómez-Gómez M; Rial E; Aller P
Biochem Pharmacol; 2012 Dec; 84(12):1604-16. PubMed ID: 23041229
[TBL] [Abstract][Full Text] [Related]
3. Increased apoptotic efficacy of lonidamine plus arsenic trioxide combination in human leukemia cells. Reactive oxygen species generation and defensive protein kinase (MEK/ERK, Akt/mTOR) modulation.
Calviño E; Estañ MC; Simón GP; Sancho P; Boyano-Adánez Mdel C; de Blas E; Bréard J; Aller P
Biochem Pharmacol; 2011 Dec; 82(11):1619-29. PubMed ID: 21889928
[TBL] [Abstract][Full Text] [Related]
4. Curcumin stimulates reactive oxygen species production and potentiates apoptosis induction by the antitumor drugs arsenic trioxide and lonidamine in human myeloid leukemia cell lines.
Sánchez Y; Simón GP; Calviño E; de Blas E; Aller P
J Pharmacol Exp Ther; 2010 Oct; 335(1):114-23. PubMed ID: 20605902
[TBL] [Abstract][Full Text] [Related]
5. Genistein selectively potentiates arsenic trioxide-induced apoptosis in human leukemia cells via reactive oxygen species generation and activation of reactive oxygen species-inducible protein kinases (p38-MAPK, AMPK).
Sánchez Y; Amrán D; Fernández C; de Blas E; Aller P
Int J Cancer; 2008 Sep; 123(5):1205-14. PubMed ID: 18546268
[TBL] [Abstract][Full Text] [Related]
6. Combination therapy with 5-amino-4-imidazolecarboxamide riboside and arsenic trioxide in acute myeloid leukemia cells involving AMPK/TSC2/mTOR pathway.
Chen L; Han F; Qu H; Yan H; Ren L; Yang S
Pharmazie; 2013 Feb; 68(2):117-23. PubMed ID: 23469683
[TBL] [Abstract][Full Text] [Related]
7. Regulation of death induction and chemosensitizing action of 3-bromopyruvate in myeloid leukemia cells: energy depletion, oxidative stress, and protein kinase activity modulation.
Calviño E; Estañ MC; Sánchez-Martín C; Brea R; de Blas E; Boyano-Adánez Mdel C; Rial E; Aller P
J Pharmacol Exp Ther; 2014 Feb; 348(2):324-35. PubMed ID: 24307199
[TBL] [Abstract][Full Text] [Related]
8. Quercetin decreases intracellular GSH content and potentiates the apoptotic action of the antileukemic drug arsenic trioxide in human leukemia cell lines.
Ramos AM; Aller P
Biochem Pharmacol; 2008 May; 75(10):1912-23. PubMed ID: 18359480
[TBL] [Abstract][Full Text] [Related]
9. High-dose ascorbate and arsenic trioxide selectively kill acute myeloid leukemia and acute promyelocytic leukemia blasts in vitro.
Noguera NI; Pelosi E; Angelini DF; Piredda ML; Guerrera G; Piras E; Battistini L; Massai L; Berardi A; Catalano G; Cicconi L; Castelli G; D'Angiò A; Pasquini L; Graziani G; Fioritoni G; Voso MT; Mastrangelo D; Testa U; Lo-Coco F
Oncotarget; 2017 May; 8(20):32550-32565. PubMed ID: 28427227
[TBL] [Abstract][Full Text] [Related]
10. BIMEL is a key effector molecule in oxidative stress-mediated apoptosis in acute myeloid leukemia cells when combined with arsenic trioxide and buthionine sulfoximine.
Tanaka Y; Komatsu T; Shigemi H; Yamauchi T; Fujii Y
BMC Cancer; 2014 Jan; 14():27. PubMed ID: 24428916
[TBL] [Abstract][Full Text] [Related]
11. Selected polyphenols potentiate the apoptotic efficacy of glycolytic inhibitors in human acute myeloid leukemia cell lines. Regulation by protein kinase activities.
de Blas E; Estañ MC; Del Carmen Gómez de Frutos M; Ramos J; Del Carmen Boyano-Adánez M; Aller P
Cancer Cell Int; 2016; 16(1):70. PubMed ID: 27610044
[TBL] [Abstract][Full Text] [Related]
12. Downregulation of Mcl-1 through GSK-3β activation contributes to arsenic trioxide-induced apoptosis in acute myeloid leukemia cells.
Wang R; Xia L; Gabrilove J; Waxman S; Jing Y
Leukemia; 2013 Feb; 27(2):315-24. PubMed ID: 22751450
[TBL] [Abstract][Full Text] [Related]
13. Synergistic antiproliferative effect of arsenic trioxide combined with bortezomib in HL60 cell line and primary blasts from patients affected by myeloproliferative disorders.
Canestraro M; Galimberti S; Savli H; Palumbo GA; Tibullo D; Nagy B; Guerrini F; Piaggi S; Cine N; Metelli MR; Petrini M
Cancer Genet Cytogenet; 2010 Jun; 199(2):110-20. PubMed ID: 20471514
[TBL] [Abstract][Full Text] [Related]
14. Pharmacologic inhibitors of PI3K/Akt potentiate the apoptotic action of the antileukemic drug arsenic trioxide via glutathione depletion and increased peroxide accumulation in myeloid leukemia cells.
Ramos AM; Fernández C; Amrán D; Sancho P; de Blas E; Aller P
Blood; 2005 May; 105(10):4013-20. PubMed ID: 15665116
[TBL] [Abstract][Full Text] [Related]
15. Pharmacologic inhibitors of extracellular signal-regulated kinase (ERKs) and c-Jun NH(2)-terminal kinase (JNK) decrease glutathione content and sensitize human promonocytic leukemia cells to arsenic trioxide-induced apoptosis.
Ramos AM; Fernandez C; Amrán D; Esteban D; de Blas E; Palacios MA; Aller P
J Cell Physiol; 2006 Dec; 209(3):1006-15. PubMed ID: 16972261
[TBL] [Abstract][Full Text] [Related]
16. Modulation of arsenic trioxide-induced apoptosis by genistein and functionally related agents in U937 human leukaemia cells. Regulation by ROS and mitogen-activated protein kinases.
Sánchez Y; Calle C; de Blas E; Aller P
Chem Biol Interact; 2009 Nov; 182(1):37-44. PubMed ID: 19720055
[TBL] [Abstract][Full Text] [Related]
17. Interaction between arsenic trioxide and human primary cells: emphasis on human cells of myeloid origin.
Binet F; Antoine F; Girard D
Inflamm Allergy Drug Targets; 2009 Mar; 8(1):21-7. PubMed ID: 19275690
[TBL] [Abstract][Full Text] [Related]
18. Metformin potentiates the effect of arsenic trioxide suppressing intrahepatic cholangiocarcinoma: roles of p38 MAPK, ERK3, and mTORC1.
Ling S; Xie H; Yang F; Shan Q; Dai H; Zhuo J; Wei X; Song P; Zhou L; Xu X; Zheng S
J Hematol Oncol; 2017 Feb; 10(1):59. PubMed ID: 28241849
[TBL] [Abstract][Full Text] [Related]
19. Synergistic effect of arsenic trioxide and flt3 inhibition on cells with flt3 internal tandem duplication.
Takahashi S; Harigae H; Yokoyama H; Ishikawa I; Abe S; Imaizumi M; Sasaki T; Kaku M
Int J Hematol; 2006 Oct; 84(3):256-61. PubMed ID: 17050201
[TBL] [Abstract][Full Text] [Related]
20. [Synergistic lethal effect of combined treatment of arsenic trioxide and aclacinomycin on human acute myeloid leukemia cell line KG-1a].
Ye YB; Xu XJ; Chen YH; Zhang MW; Qiu DF; Guo ZW; He HQ
Zhonghua Zhong Liu Za Zhi; 2017 Apr; 39(4):256-262. PubMed ID: 28550664
[No Abstract] [Full Text] [Related]
[Next] [New Search]
